AccessibilityHelpAbout Us
Takeda Pharmaceutical logo

Takeda Pharmaceutical(OTC) TKPHF

Market Cap$57.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+7%
5 Year+35%
1 Year+22%
1 Month+8%
$36.20
+2.43%
+0.86Today
Takeda Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 36.202026-09-14
Takeda Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.64%USD 36.802026-09-04
1 month+7.94%USD 33.532026-08-14
3 month+11.44%USD 32.482026-06-16
Year to date+19.57%USD 30.272025-12-31
1 year+22.12%USD 29.642025-09-11
3 year+25.71%USD 28.792023-09-15
5 year+34.91%USD 26.832021-09-15
Since inception+6.57%USD 33.962003-06-30

Takeda Pharmaceutical Financials at a Glance

Market Cap

$57.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥4.63T

Net Income (TTM)

¥180.65B

EPS (TTM)

-$0.67

P/E Ratio

-54.70

Dividend

$1.30

Beta (Volatility)

0.06 (Low)

Price

$36.20

Volume

100

Open

$36.20

Previous Close

$36.20

Daily Range

$36.20 - $36.20

52-Week Range

$26.33 - $39.20

Estimated Earnings Date

Oct 29, 2026

TKPHF News

GettyImages-1166057429

Why Is Everybody Talking About Novavax Stock?

Taylor CarmichaelDec 30, 2020
immu

Why ImmunoGen Inc. is Soaring Higher Today

Todd CampbellMar 23, 2015

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader based in Tokyo, Japan, with a rich history dating back to 1781. The company is dedicated to the research, development, production, and commercialization of innovative medicines across various therapeutic areas, including gastroenterology, oncology, and rare diseases.

Products and Services
  • Focus on therapeutic areas such as digestive health and oncology
  • Notable products include Entyvio, Takhzyro, and Velcade
  • Engages in strategic partnerships for research and development
Growth Outlook
  • Recent quarterly revenue reached JPY 1.22 trillion, a significant increase
  • Strong focus on expanding product pipeline in rare diseases and oncology
  • Strategic collaborations enhance innovation and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of JPY 4.5 trillion
  • Net income for the latest quarter was JPY 113.2 billion
  • Dividend yield stands at 3.41%, reflecting shareholder returns
Takeda Pharmaceutical Company Limited has established itself as a formidable player in the biopharmaceutical industry, leveraging its extensive experience and innovative capabilities. The company's commitment to addressing unmet medical needs through its diverse product portfolio positions it well for future growth. Recent financial performance indicates a robust revenue trajectory, with a notable increase in quarterly revenue, underscoring the effectiveness of its strategic initiatives. The focus on rare diseases and oncology, combined with strong partnerships, enhances its potential for sustained growth. Investors may find Takeda's commitment to innovation and shareholder returns appealing as it navigates the evolving healthcare landscape.
AI Generated • Aug 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

47,029

CEO

Julie So-Young Kim

Website

www.takeda.com

Headquarters

Tokyo, OS 103-8668, JP

TKPHF Financials

Key Financial Metrics (TTM)

Gross Margin

62.15%

Operating Margin

10.52%

Net Income Margin

3.91%

Return on Equity

2.40%

Return on Capital

4.27%

Return on Assets

1.15%

Earnings Yield

-1.83%

Dividend Yield

3.60%

Payout Ratio

1.75%

Stock Overview

Market Cap

$57.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.59B

Volume

100

Avg. Volume

40.39K

Financials (TTM)

Gross Profit

¥2.73T

Operating Income

¥508.18B

EBITDA

¥1.31T

Operating Cash Flow

¥895.45B

Capital Expenditure

-¥194.96B

Free Cash Flow

¥700.49B

Cash & ST Invst.

¥527.58B

Total Debt

¥4.94T

Takeda Pharmaceutical Performance Analysis

Takeda Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 29,731,234,709-6.4%
20242024-03-31JPY 29,524,693,129-0.7%
20252025-03-31JPY 30,052,738,4511.8%
20262026-03-31JPY 29,900,176,919-0.5%
Takeda Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-300.6%
Q32025-12-317.2%
Q42026-03-31-7.7%
Q12026-06-3010.8%
Takeda Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.4914.8%
20242024-03-31JPY 0.63-57.7%
20252025-03-31JPY 0.44-30.1%
20262026-03-31JPY -0.64N/A
Takeda Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-109.6%
Q32025-12-31965.4%
Q42026-03-31-124.2%
Q12026-06-30550.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

¥1.22T

+10.2%

Gross Profit

¥813.22B

+12.6%

Gross Margin

66.66%

N/A

Market Cap

$57.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.22M

N/A

Employees

47,029

N/A

Net Income

¥113.20B

-8.9%

EBITDA

¥337.49B

-23.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

¥527.58B

+25.9%

Total Debt

¥4.94T

+9.6%

Accounts Receivable

¥956.14B

+40.7%

Inventory

¥1.45T

+16.7%

Long Term Debt

¥4.42T

+6.9%

Short Term Debt

¥519.97B

+40.1%

Return on Assets

1.15%

N/A

Return on Invested Capital

3.77%

N/A

Free Cash Flow

¥73.81B

-47.4%

Operating Cash Flow

¥127.62B

-40.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPSEYIpsen S.A.
$45.92-1.25%
HOCPFHOYA Corporation
$144.26+0.00%
LZAGYLonza Group AG
$65.71+0.47%
WUXIFWuXi AppTec Co., Ltd.
$24.53-8.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$6.17+169.43%
BITOProShares Trust - ProShares Bitcoin ETF
$10.22-3.72%
NOKNokia
$9.88+2.33%
AALAmerican Airlines Group
$12.80-2.33%

Questions About TKPHF

What is the current price of Takeda Pharmaceutical?

Takeda Pharmaceutical is trading at $36.20 per share.

What is the 52-week range for Takeda Pharmaceutical?

Over the past 52 weeks, Takeda Pharmaceutical has traded between $26.33 and $39.20.

How much debt does Takeda Pharmaceutical have?

As of the most recent reporting period, Takeda Pharmaceutical reported total debt of ¥30.40B.

How much cash does Takeda Pharmaceutical have on hand?

Takeda Pharmaceutical reported ¥2.84B in cash and cash equivalents in its most recent financial results.

What is Takeda Pharmaceutical’s dividend yield?

Takeda Pharmaceutical currently has a dividend yield of 3.60%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services